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This issue of Clinical Microbiology and Infection is dedicated to
invasive fungal infections (IFI) based on the ESCMID confer-
ence held in Rome on January 2013. The reviews summarize
the progress achieved in the ﬁelds of epidemiology, diagnosis
and management of Candida, Aspergillus and Mucor invasive
infections.
Epidemiology
Candida spp. have become important causes of sepsis in
hospitals with incidence constantly growing over the last
20 years. Candida spp. is now the 4th most common isolate of
bloodstream infections in many countries (and the most
common IFI), mainly due to the increasing complexity of
medical care [1]. Candida albicans is still the main cause of
candidemia in population-based studies worldwide, but its
relative frequency is decreasing, while the frequency of the
other species is increasing. Patients’ characteristics inﬂuence
Candida species distribution; C. glabrata infections are more
common in the elderly, C. krusei in immunocompromised
patients, while C. parapsilosis is most common in children and
neonates. Risk factors for candidemia include neutropenia,
especially during periods of mucositis, broad spectrum
antibiotic therapy, abdominal surgery mainly involving the
colon, total parenteral nutrition and combination of such risk
factors.
Invasive aspergillosis is the second most common IFI, with
increasing incidence over the last 20 years along with the
advances in the treatment of hematological malignancies.
Prolonged neutropenia is the main risk factor. Patients with
acute myeloid leukaemia (AML) and those who undergo
allogeneic hematopoietic stem cell transplantation (HSCT)
have prolonged durations (more than 10 days) of neutropenia
and are at highest risk. In the highest risk group, invasive
aspergillosis rates can reach 25% [2]. An optimal risk score for
invasive aspergillosis would have to include ﬁne details on the
underlying malignancy and its predicted response to chemo-
therapy, chemotherapy regimens, allogeneic transplantation
and the presence of GVHD. However, the incidence of
invasive aspergillosis is very much dependent on local epide-
miology and the quality of air control in hemato-oncological
units. Thus, in some settings, invasive aspergillosis is more
frequent than invasive candidiasis [2].
Mucormycosis is the second most common invasive mould
infection and its incidence increased from 0.7 per million in
1997 to 1.2 per million in 2006 [3]. In addition to immune-
suppression, there are some unique host risk factors for
mucormycosis such as diabetes keto-acidosis, burns, iron
overload and, on the other hand, deferoxamine therapy. The
speciﬁc clinical syndrome of mucormycosis is associated with
host risk factors; thus, pulmonary mucormycosis is more
common in patients with hematological malignancies, while
rhino-cerebral mucormycosis is more common in diabetic
patients [4]. The aetiologic agents involved in the disease have
been reclassiﬁed in recent years, based on molecular methods
establishing taxonomy [4]. Thus, “zygomycosis” was reclassi-
ﬁed to either “mucormycosis” or “entomophthoromycosis”. It
appears that genera that belong to the subphylum mucormy-
cotina are ubiquitous worldwide and cause severe life-threat-
ening infections in immunocompromised patients, while
entomophthoromycotina are found in tropical regions and
cause chronic subcutaneous infections in otherwise healthy
patients. Early identiﬁcation of mucor spp. to the species level
and advances in epidemiological data will perhaps allow in the
future better prediction of patients’ prognosis and tailoring of
treatment.
Diagnostics
Traditional microbiological tests are not sensitive enough for
the diagnosis of fungal infections. It has been shown that blood
cultures may fail to diagnose candidemia in up to 50% of the
cases [5]. In mould infections, the sensitivity of culture is even
lower. This led to the development of noncultural serological
and molecular tests, for the diagnosis of invasive fungal disease.
Of the serological tests, the galactomannan antigen for
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aspergillus and 1-3 beta-D-glucan for fungal infections other
than cryptococcosis and zygomycoses are included in the
diagnostic criteria for IFI [6]. Galactomannan detection in the
BAL ﬂuid has higher sensitivity and speciﬁcity for diagnosing
invasive pulmonary aspergillosis than serum [7]. PCR-based
tests have not reached the same level of acceptance, mainly
due to lack of standardization in the type of clinical sample
(serum, plasma, tissue), primer selection (“pan-fungal”, species
speciﬁc) and PCR format (qualitative vs. quantitative, real
time) [8]. Systematic reviews support the diagnostic potential
of such tests. Thus, using acceptable diagnostic criteria (other
than PCR), systematic reviews have summarized that PCR in
blood had a sensitivity of 0.88 (95% CI 0.75–0.94) for diagnosis
of IA if a single positive sample was required to deﬁne
positivity and a speciﬁcity 0.87 (95% CI 0.78–0.93) if two
positive samples deﬁned test positivity [9]; PCR in bronchoal-
veolar lavage had a sensitivity and speciﬁcity of 0.91 (95% CI
0.79–0.96) and 0.92 (95% CI 0.87–0.96), respectively, for the
diagnosis of invasive pulmonary aspergillosis [10]; and PCR in
blood had a sensitivity of 0.95 (95% CI 0.88–0.98) and
speciﬁcity of 0.92 (95% CI 0.88–0.95) among patients at risk of
diagnosis of invasive candidiasis [11]. Variability in PCR
methods was responsible for some of the heterogeneity in
the meta-analyses, but the ability of systematic reviews to
identify optimal PCR techniques is limited by the multitude of
method components and their interactions. Deﬁning a stan-
dard methodology should be performed basing the summary
of diagnostic study ﬁndings but also relying on expert opinion.
The future will probably see the incorporation of molecular
tests in diagnostic algorithms and criteria.
Prophylaxis
Antifungal prophylaxis has been shown to reduce mortality
among high-risk hemato-oncological patients [12]. A recent
network meta-analysis of RCTs [13], including direct and
indirect comparisons, summarized that ﬂuconazole, itraco-
nazole solution, voriconazole, posaconazole, low dose
liposomal amphotericin B and micafungin have the potential
to signiﬁcantly reduce total IFI rates (compared with no
treatment). Posaconazole and voriconazole have been esti-
mated as more effective than ﬂuconazole and itraconazole
capsules (that are poorly absorbed) with regard to IFIs with
more data supporting posaconazole. Itraconazole oral
suspension has better bioavailability than capsules, but poor
gastrointestinal tolerability hampers its widespread use.
Universal adoption of posaconazole is hindered by the
nonavailability of an IV formulation until now for patients
who cannot take oral treatment during periods of severe
mucositis (only recently approved [14]), costs and concerns
regarding resistance induction and the lack of treatment
options for breakthrough infections. Indeed, the downside of
any prophylaxis is its potential to increase infections caused
by resistant strains. Thus, posaconazole and itraconazole have
been associated with the appearance of C. glabrata with
decreased azole susceptibility and ﬂuconazole was associated
with the appearance of C. glabrata and C. krusei [15]. Voric-
onazole, itraconazole and caspofungin have been associated
with appearance of Mucor spp. infections [16,17]. Centres
need to deﬁne local protocols for antifungal prophylaxis
based on their local epidemiology of candidemias and
incidence of invasive aspergillosis. The rates of invasive
aspergillosis without antimould prophylaxis in recent RCTs of
posaconazole and voriconazole averaged 7–8% of patients at
100 days. Thus, evidence is relevant for settings with similar
incidence. Although RCTs have focused on the main patient
populations, that is, AML induction, allogeneic transplantation
with GVHD, prophylaxis might need to be extended to other
patients, not speciﬁcally examined in RCTs, based on their
risk of IFIs.
Pre-emptive vs. Empirical Treatment
In 1982, Pizzo et al. showed that empirical antifungal therapy
with amphotericin B in patients with cancer with prolonged
fever with granulocytopenia reduce the number of IFIs and
fungal deaths [18]. This practice soon became part of the
guidelines for management of febrile neutropenic patients.
With the development of modern imaging and serological/
molecular markers, which allow early detection of IFI, the
“pre-emptive” strategy became optional, where IFIs are
actively searched for and antifungal treatment is started when
there is an indication of IFI other than fever (“diagnostic
driven” strategy) [19]. The rationale for pre-emptive treat-
ment is to decrease treatment-related toxicity, costs and
resistance emergence and perhaps to improve patient out-
comes through more tailored treatment. Currently published
RCTs show that the pre-emptive strategy is not necessarily
associated with reduced antifungal use (although in 2/3 studies
it was) and usually leads to the diagnosis of more IFIs [20–22].
All-cause mortality was not signiﬁcantly affected in the three
trials, although only one trial was designed to examine survival
[20]. Compiling or comparing between these studies is
difﬁcult because the diagnostic and management pathways of
empirical and pre-emptive strategies were heterogeneous.
Thus, the debate regarding empirical vs. pre-emptive treat-
ment is open, with a trend favouring the more tailored pre-
emptive strategy in an attempt to improve patients’ manage-
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ment [23]. With effective antimould prophylaxis, the question
is less relevant.
Treatment of Established Infections
The advances regarding the antifungal armamentarium to treat
IFIs are described in this issue. Signiﬁcant advance has also
been made in standardizing susceptibility testing. The EUCAST
and CLSI have developed breakpoints that are now established
to interpret susceptibility results for amphotericin, azoles and
echinocandins for most Candida spp. These documents are
available online and permit clinicians better interpretation and
selection of antifungals. With Aspergillus spp., MIC values do
not always directly associate with response to antifungal
therapy and work is in progress.
Despite these advances, mortality rates of IFIs remain
unacceptably high, especially among immunocompromised
patients. Mucormycosis is more difﬁcult to cure than other
mycosis and carries mortality rates of 40–70% in the immu-
nocompromised host despite treatment. This is attributed to
extensive angioinvasion, increased virulence, difﬁculties in early
diagnosis lacking a serological test, nonspeciﬁc clinical man-
ifestations and the limitations of antifungal therapy [4,24].
As with all anti-infective treatment, stewardship programmes
for judicious prescription are necessary for antifungals [25].
Unique to the treatment of infections is the issue of resistance
induction or shift toward resistant strains following treatment.
Thus, stewardship programmes must promote optimal antifun-
gal treatment on the one hand, but restrict redundant and
unnecessary antifungal use on the other hand. Of all antimicro-
bials, economic considerations apply most to antifungals,
because of the limited number of drugs available and the
signiﬁcant costs of new drugs. These considerations must also
be uniquely addressed in antifungal stewardship programmes.
In summary, signiﬁcant advance has been achieved in the
diagnosis and management of IFIs summarized in the current
theme issue and recently published guidelines [26,27]. For a
complete list of ESCMID guidelines on IFIs please see: https://
www.escmid.org/escmid_library/medical_guidelines/escmid_
guidelines/. These come in response to increasing incidence of
fungal infections in hospitals associated with increasing com-
plexity of the patient case mix and more treatment options for
patients with cancer. Obtaining unbiased evidence for man-
agement decisions is critical.
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